Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.
In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.
In this concise presentation, Dr. Daniel Kuritzkes discusses recent data on new long-acting injectable ART.
See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Listen as Daniel R. Kuritzkes, MD, explains key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Learn why one patient feels that long-acting ART gave her a lot of her life back.
In this case example, learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
Learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
In this case example, learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted.
Learn the data to help you determine when switching to 2-drug single tablet regimens may be warranted
Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.
I was hesitant to switch, but I asked my doctor a million and one questions because I think that taking an active role in your own health and being informed helps ensure you are getting the best care possible.
Long-acting regimens do not contain HBV active agents, and therefore, it is vital to assess an individual's hepatitis B status before switching.
In this case example, learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option
Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data about which patient factors may predict failure to LA CAB plus RPV and who is and who is not a good candidate for this new treatment option.
Learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.